Syndecan-1和乙酰肝素酶1在结直肠癌中的表达及对其转移和预后的影响  

The impact of mRNA expression of syndecan-1 and heparanase1 in relation to tumor progression and prognosis of colorectal cancer

作　　者：陈宇宁[1] 张毅[1] 蒋富兵 

机构地区：[1]广东省惠州市第三人民医院消化内科,广东惠州516002 [2]广东省惠州市第三人民医院胃肠外科,广东惠州516002

出　　处：《中国当代医药》2014年第12期15-17,共3页China Modern Medicine

摘　　要：目的探讨Syndecan-1和乙酰肝素酶1(heparanase 1,HPA1)在结直肠癌组织中的表达水平和对其转移和预后的影响。方法采用原位杂交技术检测177例结直肠癌组织中Syndecan-1和HPA1的表达水平,比较Syndecan-1、HPA1 mRNA表达与结直肠癌临床病理指标、疾病预后的关系。结果在177例标本中,Syndecan-1 mRNA和HPA1 mRNA的阳性例数分别为75例和99例;Syndecan-1 mRNA及HPA1 mRNA阳性表达率与肿瘤浸润深度、TNM分期、淋巴结转移、远处转移和脉管癌栓密切相关(P<0.01);Syndecan-1 mRNA水平与HPA1 mRNA表达呈负相关(P<0.01);Syndecan-1 mRNA低表达平均生存时间和5年生存率低于高表达组,HPA1 mRNA阳性表达平均生存时间和5年生存率低于阴性表达组。结论 Syndecan-1低表达和HPA1高表达对结直肠癌的侵袭和转移具有协同作用;两者结合有助于术后评估疗效和判断预后。Objective To investigate the mRNA expression of syndecan-1 and heparanase 1 in colorectal cancer,and their relationship between the progression and prognosis of the diseases. Methods In situ hybridization was used to ex- amine mRNA expression of syndecan-1 and I-IPA1 in 177 specimens of colorectal cancer.The relationship between mR- NA expression and pathology indicators as well as prognosis of disease was observed. Results The positive numbers of syndecan-1 mRNA and HPA1 mRNA were 75 cases and 99 cases.The expression of syndecan-1 mRNA and HPA1 mRNA were related to tumor invasion depth,lymph node metastasis,TNM,distant metastasis and vessel invasion （P〈 0.01）.There was a negative relationship between Syndecan-1 mRNA and HPA1 mRNA expression （P〈0.01）.The mean sur- vival time of cases with low expression of syndecan-1 mRNA was significantly shorter than that of cases with high ex- pression.The mean survival time of heparanase mRNA positive cases was significantly shorter than that of cases with negative expression. Conclusion The low expression of syndecan-1 and positive expression of HPA1 can predict the in- vasion and metastasis of colorectal cancer.They can be used as markers of progression and prognosis of colorectal cancer.

关 键 词：SYNDECAN-1 乙酰肝素酶1 结直肠癌 预后 

分 类 号：R735.3[医药卫生—肿瘤]